Narcolepsy Trial, Recruiting NCT06292598 Sponsor: Centre Hospitalier Universitaire de Nīmes Condition: Narcolepsy
Back to Narcolepsy

Narcolepsy Trial, Recruiting

NCT06292598
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with type 1 narcolepsy (a sleep disorder that causes sudden muscle weakness and excessive sleepiness).
  • You are either not yet being treated for narcolepsy (for the newly diagnosed group) or are already being monitored for narcolepsy over time (for the follow-up group).
  • You speak and understand French.
  • You have given your free and informed consent to participate (or, if you are a child, your parent or legal guardian has given consent on your behalf).
  • You are covered by a health insurance plan.

For healthy volunteers (control participants):

  • You have not been diagnosed with a sleep disorder that causes excessive daytime sleepiness, and your score on a standard sleepiness questionnaire is 10 or below out of 24.

Who may not be able to join:

  • You have had an infection requiring antibiotic treatment in the past 3 months.
  • You have a condition that affects your immune system.
  • You have received treatment that affects the immune system, or chemotherapy, within the past 60 days, or such treatment is planned during the study period.
  • You have a long-term digestive condition, or you have had weight-loss (bariatric) surgery in the past year.
  • You are currently taking laxatives.
  • You currently live in a medical or care institution.
  • You are under legal protection, guardianship, or supervised care (confirm with trial site).
  • You (or your legal representative, if you are a minor) are unable to give consent.
  • You start taking antibiotics, laxatives, or any other medication that could significantly affect gut bacteria during the enrolment period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Catherine Dunyach-Remy, CHU de Nimes

Phone: 0466683202

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire de Nīmes
Registry
ClinicalTrials.gov
Start date
10 March 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Plasma bacterial translocation profiles between groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov